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Abstract
Background: NF-κB is a transcription factor that promotes inhibition of apoptosis and resistance to chemotherapy. It is 
commonly believed that inhibition of NF-κB activity can increase sensitivity of cancer cells to chemotherapy. However, 
there is evidence that NF-κB activation can sensitize cells to apoptosis and that inhibition of NF-κB results in resistance 
to chemotherapy. In prostate cancer, it is not clear in the different cell types (androgen-dependent and castration-
resistant) if activation or inhibition of NF-κB is required for stimulation of apoptosis by chemotherapy.
Results: Our data indicate that the response of prostate cancer (PC) cells to the antimitotic drugs docetaxel (Doc) and 
2-methoxyestradiol (2ME2) is dependent on the levels of NF-κB activity. In androgen-dependent LNCaP cells, Doc and 
2ME2 treatment increased the low basal NF-κB activity, as determined by Western blot analysis of phospho-IκBα/p65, 
NF-κB promoter reporter assays, and p65 localization. Treatment of LNCaP cells with parthenolide, a pharmacologic 
inhibitor of NF-κB, or introduction of dominant-negative IκBα, or an shRNA specific for p65, a component of the NF-κB 
heterodimer, blocked apoptosis induced by Doc and 2ME2. In castration-resistant DU145 and PC3 cells, Doc and 2ME2 
had little effect on the high basal NF-κB activity and addition of parthenolide did not enhance cell death. However, the 
combination of Doc or 2ME2 with betulinic acid (BA), a triterpenoid that activates NF-κB, stimulated apoptosis in LNCaP 
and non-apoptotic cell death in DU145 and PC3 cells. Increased sensitivity to cell death mediated by the Doc or 2ME2 
+ BA combination is likely due to increased NF-κB activity.
Conclusions: Our data suggest that the combination of antimitotic drugs with NF-κB inhibitors will have antagonistic 
effects in a common type of PC cell typical of LNCaP. However, combination strategies utilizing antimitotic drugs with 
BA, an activator of NF-κB, will universally enhance cell death in PC cells, notably in the aggressive, castration-resistant 
variety that does not respond to conventional therapies.
Introduction
NF-κB, originally discovered as a transcription factor that
regulates the immune system, is now known to be widely
expressed in almost all cells and mediates multiple signal-
ing pathways including cell proliferation and survival [1].
A common form of NF-κB is a heterodimer consisting of
p 6 5  ( R e l A )  a n d  p 5 0  p r o t e i n s  t h a t  e x i s t s  a s  a n  i n a c t i v e
IκBα-bound form in the cytoplasm of unstimulated cells.
Activation of the NF-κB pathway by a variety of inducers
including cytokines, growth factors, UV light and DNA-
damaging drugs often occurs by increasing the phospho-
rylation of IκBα by the IκB kinase (IKK) complex. This
results in ubiquitination and rapid degradation of IκBα by
the 26S proteasome, allowing for the increase of nuclear
NF-κB DNA binding activity and transcriptional activa-
tion of its target genes, including Inhibitor of Apoptosis
(IAP) family members XIAP, IAP-1, IAP-2 and anti-apop-
totic Bcl-2 family members Bcl-2, Bcl-xL [1]. Therefore,
NF-κB activation is often associated with increased sur-
vival of cancer cells and resistance to chemotherapy.
Accordingly, there are several candidate inhibitors of NF-
κB activity that are in development as anti-cancer therapy
[2-4].
However, the role of NF-κB in cancer progression and
in anti-cancer therapeutics is complex, as there is also
evidence to suggest that NF-κB activation can sensitize
cells to apoptosis [5,6]. For example, inhibition or loss of
NF-κB activity blocks p53-mediated apoptosis, suggest-
ing that inhibition of NF-κB in p53 positive tumors may
weaken the therapeutic response [7]. Furthermore, acti-
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vation of NF-κB by UV light and doxorubicin converts it
into an active repressor of the anti-apoptotic genes XIAP
and Bcl-xL [8]. Additional evidence supporting a pro-
apoptotic role for NF-κB in cancer chemotherapy comes
from the observation that the retinoid-related com-
pounds 3-Cl-AHPC and CD437 require activation of NF-
κB in order to induce apoptosis in DU145 and PC3 cas-
tration-resistant prostate cancer (CRPC) cells [9,10].
Exposure of CRPC cells to 3-Cl-AHPC or CD437
enhances the expression of the pro-apoptotic Death
Receptor (DR) 4 and 5 genes. An NF-κB binding site
located in intron 1 of the DR5 promoter is important for
positive regulation by NF-κB [11]. Activation of NF-κB by
betulinic acid (BA), a naturally occurring pentacyclic trit-
erpenoid small molecule with anticancer properties, is
also required for induction of apoptosis in tumor cells
[12].
The clinical progression of prostate cancer (PC)
involves the transition from androgen-dependent cancer,
which can be successfully treated with androgen-ablation
therapy, to a castration-resistant cancer with few treat-
ment options [13]. One of the critical factors in the pro-
gression to CRPC is the increased activity of NF-κB and
its promotion of apoptotic inhibition [14-16]. It is not
clear in the different types of PC cells (androgen-depen-
dent and castration- resistant) whether activation or inhi-
bition of NF-κB is required for stimulation of apoptosis
by chemotherapy. Since PC consists of a heterogeneous
mixture of cell types, it is important to better understand
the mechanisms of the effect of chemotherapy on NF-κB
activity in different PC cell lines in order to increase ther-
apeutic response [17,18].
In this report, we investigate the effects of the antimi-
totic drugs docetaxel (Doc) and 2-methoxyestradiol
(2ME2) on NF-κB activity and induction of cell death in
androgen-responsive and castration-resistant PC cell
lines. Doc is now one of the most effective anti-cancer
drugs and is FDA approved for the treatment of prostate,
breast, gastric, head and neck, and non-small cell lung
cancers [19,20]. 2ME2, an endogenous metabolite of
estradiol, is being investigated in clinical trials as an anti-
cancer agent [21]. Both Doc and 2ME2 have been
reported to increase NF-κB activity in tumor cell lines
including PC, but whether this stimulates or antagonizes
apoptosis appears to be dependent on the specific tumor
cell type [22,23].
Studies have shown constitutive NF-κB DNA binding
and transcriptional activity in DU145 and PC3 CRPC
cells but not in androgen-dependent LNCaP cells [24-26].
Our data indicated that both Doc and 2ME2 increased
NF-κB activity in LNCaP cells and that inhibition of NF-
κB was able to block treatment-induced apoptosis. Doc
and 2ME2 treatment had little effect on NF-κB activity in
DU145 and PC3 cells and the addition of an NF-κB inhib-
itor did not stimulate cell death in these cells. In contrast,
addition of BA increased NF-κB activity and stimulated
Doc- and 2ME2-mediated apoptosis in LNCaP and cas-
pase-independent cell death in DU145 and PC3 cells.
Materials and methods
Reagents
2ME2 was obtained from EntreMed, Inc. and Doc from
Aventis Pharmaceuticals. Parthenolide and 4'-6-Diamid-
ino-2-phenylindole (DAPI) were purchased from Calbio-
chem; BA from Calbiochem, Biomol, or AG Scientific;
Trypan blue (0.4%) from Invitrogen; and Coomassie blue
from EMD Chemicals, Inc.
Cell Culture
Human PC cell lines LNCaP, DU145, and PC3 were
obtained from the American Type Culture Collection
[27]. LN-AI is a castration-resistant subline of LNCaP,
which was spontaneously derived in our laboratory [28].
These cells express androgen receptor (AR) and prostate-
specific antigen (PSA), similar to LNCaP. DU145 and PC3
cells do not express AR or PSA. All cells were maintained
in RPMI 1640 medium (Invitrogen) with 5% fetal bovine
serum (Hyclone), 100 U/ml penicillin, 100 μg/ml strepto-
mycin, and 0.25 μg/ml amphotericin (Invitrogen). Media
for LN-AI/dnI clones 7, -20, and LN-AI/neo cells also
contained 200 μg/ml G418 (Invitrogen).
Drug Treatments
PC cells were cultured in media containing 2ME2 (5 μM),
Doc (1 nM), parthenolide (10 μM), BA (10 μM) or DMSO
control for varying times (24-72 h). In all the experi-
ments, adherent and non-adherent cells were pooled for
further analysis.
Western Blot Analysis
Preparation of total protein lysates was done as previ-
ously described [28]. Preparation of nuclear extracts was
done using NE-PER nuclear extraction reagents as per
manufacturer's instructions (Pierce Biotechnology). After
separation of 25-50 μg protein by SDS-PAGE, proteins
were transferred by electrophoresis to Immobilon-P
membrane and incubated in 5% nonfat dry milk, TBS,
and 0.1% Tween-20 for 1 h. Antibodies specific for phos-
pho-(Ser32/36) IκBα (9246), IκBα (9242), phospho
(Ser536)-p65 (3031), cleaved PARP (Asp 214), and XIAP
(2042) from Cell Signaling; p65 (C-20), p53 (DO-1), and
AIF/N-terminus (E-1) from Santa Cruz Biotechnology;
and AIF/C-terminus (A7549) from Sigma-Aldrich were
diluted 1/1,000-1/3,000 in 5% nonfat dry milk, TBS, and
0.1% Tween-20 and incubated overnight at 4°C. Mem-
branes were washed in TBS and 0.1% Tween-20 and incu-
bated with the appropriate horseradish peroxidase-
conjugated secondary antibody (1/3,000 dilution; Santa
Cruz) for 1 h, washed in TBS and 0.1% Tween-20, andParrondo et al. Molecular Cancer 2010, 9:182
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analyzed by exposure to X-ray film using enhanced
chemiluminescence plus (ECL plus, GE Healthcare Bio-
Sciences Corp). Staining of total protein with Coomassie
blue was used as a protein loading control. X-ray films
were scanned using an Epson Perfection 2450 Photo
scanner.
NF-κB Reporter Assay
To measure NF-κB transcription activity, we used a plas-
mid containing the luciferase reporter gene regulated by
four copies of NF-κB cis-acting elements linked to TATA
box from the thymidine kinase promoter (NF-κB-TA/luc;
Clontech). TA/Luc is the negative control plasmid with-
out NF-κB elements. Plasmids were co-transfected with
CMV/β-galactosidase (Clontech) into LNCaP and PC3
cells using FuGene 6 HD transfection reagent (Roche), as
previously described [29]. After 24 h, transfected cells
were grown in the presence or absence of 5 μM 2ME2 for
24 and 72 h and the luciferase and β-gal activities deter-
mined. The NF-κB luciferase activity relative values as
light units/β-gal were divided by TA/luc values and
expressed as fold above TA/luc from 3 independent
experiments done in duplicate.
Fluorescence Immunocytochemistry
Adherent and non-adherent cells were harvested, fixed in
formalin for 5 min, applied to slides by smearing, air
dried, rinsed with PBS, and blocked with M.O.M. (Vector
Laboratories) or goat serum for 20 min. For double
immunofluorescence, after first immunostaining for p65
(1:50 dilution; 30 min), we used biotinylated anti-rabbit
IgG (1/200 dilution; Vector Laboratories) for 20 min, flu-
orescein Avidin DCS (1/300 dilution; Vector Laborato-
ries) for 5 min., followed by avidin/biotin blocking for 15
min, immunostaining with nucleolin (H-250; Santa Cruz
Biotechnology) for 30 min, biotinylated anti-rabbit IgG,
Texas Red DCS, and mounting media with DAPI stain
(Vector Laboratories). AIF was immunostained using
AIF/N-terminus (1:25 dilution), biotinylated anti-mouse
IgG (1/200 dilution; Vector Laboratories), Fluorescein
Avidin DCS, and mounting media with propidium iodide
(PI) (Vector Laboratories). Color images were acquired
using a Nikon Eclipse 90i fluorescence microscope with
FITC/Texas Red filters and merged using Adobe Photo-
shop 7.
DAPI Apoptosis and Trypan Blue Exclusion Assays
The DAPI staining apoptosis assay was done as previ-
ously described [28]. Changes in apoptosis in cells treated
with drugs were determined as percentage of apoptotic
cells (densely stained and fragmented chromatin) from 3-
6 independent experiments done in duplicate. Minimal
apoptosis was detected in control treated cells (<0.5%).
For the trypan exclusion assay, treated and control pros-
tate cancer cells were harvested, resuspended in growth
media, diluted 1:1 in 0.4% trypan blue, dead blue and live
non-blue cells immediately counted using a hemacytom-
eter, and the % dead blue cells determined from at least 3
independent experiments done in duplicate.
Annexin-FITC/Propidium Iodide (PI) Flow Cytometry
For the annexin apoptosis assay, we used the ApoAlert
Annexin V-FITC Apoptosis kit (Clontech). LN-AI and
DU145 cells were resuspended in binding buffer followed
by the addition of annexin V-FITC and PI. After 20 min.,
cells were analyzed by flow cytometry using a Coulter XL
flow cytometer and the percentage of annexin+ and PI+
cells determined using WinMDI version 2.8.
Stable Transfection of Dominant Negative IκBα
To inhibit endogenous NF-κB activity, we obtained the
pCMV-IκBαM plasmid (Clontech) expressing dominant
negative IκBα containing Ser to Ala mutations at posi-
tions 32 and 36, which cannot be phosphorylated and
degraded [30]. LN-AI cells (90% confluent) were co-
transfected with pCMV-IκBαM and pCMVneo (for drug
selection) using FuGene 6 HD following the manufac-
turer's instructions. The negative control was transfec-
tion with pCMVneo alone. Cells were initially grown in
media with 400 μg/ml G418 (Invitrogen), colonies
selected, and clones that express dominant negative-IκBα
(dnI) compared to pCMVneo negative control cells clones
were identified by Western blot (migrates faster than
endogenous wild type IκBα).
Lentiviral Transduction of LNCaP and DU145 with shRNA 
Against p65 and AIF
The shRNA design, lentivirus production and infection
were done as previously described [31]. The following
DNA oligonucleotides (Operon Technologies) targeting
p65 and AIF were cloned into pLKO.1 lentivirus vector:
shp65-1: GGCGGATTGAGGAGAAACGTAAACTCG
AGTTTACGTTTC TCCTCAATCCGTTTTTG; shp65-
2: CCGGCCTGAGGCTATAACTCG CCTACTCGAG-
TAGGCGA GTTATAGCCTCAGGTTTTTG; shAIF-1:
CCGGCCTGGAAA TAGACTCAGATTT CTCGA-
GAAATCTGAGTCTATTTCCAGGTTTTTG; shAIF-2:
CCGG CTGCATGCTTCTACGATATAACTCGAG TTA
TATCGTAGA AGCATGCAGTTTTTG. The control
shRNA was targeted against GFP. LNCaP/shp65-2,
LNCaP/shAIF-2, LNCaP/shGFP, DU145/sh p65-1,
DU145/shAIF-1, and DU145/shGFP were further ana-
lyzed.
Real Time Quantitative Polymerase Chain Reaction (RT-
qPCR)
RNA was isolated from prostate cancer cells using
QIAshredder and RNeasy miniprep kit (Qiagen Inc.). AllParrondo et al. Molecular Cancer 2010, 9:182
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RNAs were treated with RNase-free DNase (Ambion) to
remove possible DNA contamination. The following
DNA oligonucleotides (Operon Technologies) were used
for RT-qPCR: AIFsh sense 5'-TCATGCCCACTGTCCT-
GTAAGT-3' and antisense 5'-CCATGG TCCAGTT-
GCTGAGGT-3' (239 amplicon) [32]; IκBα sense 5'-
CTCCGAGACTTTCGAGG AAATAC-3' and antisense
5'-GCCATTGTAGTTGGTAGCCTTCA-3' (135 ampli-
con) [33]; A20 sense 5'-AAGCTGTGAAGATACGG-
GAGA-3' and antisense 5'-CGATGAGGGCTTT GTG
GATGAT-3' (159 amplicon) [33]; DR5 sense 5'-AAGAC-
CCTTGTGCTCGTTGT-3' and antisense 5'-AGGTG-
GACACAATCCCTCTG-3' (144 amplicon) [33]; and the
reference gene ribosomal protein, large, P0 (RPL0) sense
5'-GCAATGTTGCCAGTGTCTG-3' and antisense 5'-
GCCTTGACCTTTTCAGCAA-3' (141 amplicon) [34].
cDNA was synthesized with the iScript cDNA synthesis
kit (Bio-Rad) and qPCR with Brilliant II Sybr Green
QPCR Kit at 30 sec at 95°C, 1 min at 55°C, and 30 sec at
72°C for 40 cycles using a MX3005 qPCR system (Strata-
gene). Crossing point values from logarithmic amplifica-
tion profiles for target genes were divided by values from
the RPL0 reference gene from RNA samples and pre-
sented as fold above control treated cells analyzed five
times from three independent experiments. Each product
was confirmed for the expected size by agarose gel elec-
trophoresis.
Statistical Analysis
Statistical differences between drug-treated and control
PC cells were determined by two-tailed Student's t-test
with P < 0.05 considered significant.
Results
To evaluate the effect of the antimitoic drugs 2ME2 and
Doc on NF-κB activity in human PC cells, we used andro-
gen-dependent LNCaP and castration-resistant LN-AI,
DU145, and PC3 cells. LNCaP and LN-AI cells contain
wild-type p53 and exhibit higher sensitivity to 2ME2 and
Doc apoptosis relative to DU145 and PC3, which are p53
mutated or null and thus are more resistant to apoptosis
[27,28,35-37].
Antimitotic Drugs Activate NF-κB in LNCaP Cells
To determine the effect of 2ME2 and Doc on NF-κB, we
analyzed phosphorylation of IκBα and of p65 at the serine
536 position, which can enhance the transcriptional
activity of NF-κB and lower its affinity to IκBα [1]. West-
ern blot analysis of LNCaP cells treated with 5 μM 2ME2
for 24 h resulted in increased phospho-IκBα (decrease in
total IκBα) and phospho-p65 (no change in total p65) rel-
ative to control treated cells (Fig. 1A). In DU145 and PC3
cells, which unlike LNCaP cells have constitutively active
NF-κB, there were no differences in phospho-IκBα or
Figure 1 2ME2 increases NF-κB activity in LNCaP but not in 
DU145 or PC3 cells. A. Western blot analysis showing that treatment 
of LNCaP but not in DU145 or PC3 cells with 5 μM 2ME2 (M) for 24 h 
increases phospho (P)-IκBα and P-p65 compared to control (C). Total 
levels of IκBα and p65 do not change, except for a decrease of IκBα in 
LNCaP. Coomassie blue stain of total protein is loading control. B. 
Western blot analysis showing that 2ME2 (M; 5 μM) and Doc (D; 1 nM) 
decrease IκBα levels at 48 and 72 h in LNCaP and LN-AI compared to 
control (C) cells. In DU145 cells, M and D did not decrease IκBα levels. 
C. Luciferase reporter assay showing that 2ME2 increases NF-κB activity 
(fold above TK promoter) in LNCaP cells at 24 h and remains high at 72 
h compared to control (C) cells. In PC3 cells, the basal NF-κB activity is 
7.3-fold higher compared to LNCaP cells and 2ME2 reduces activity af-
ter 24 h. After 72 h, NF-κB activity is similar to control cells. n = 6, three 
independent experiments; *, P < 0.02.
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phospho-p65 in 2ME2-treated cells relative to control
cells (Fig. 1A). In addition, total IκBα protein decreased in
2ME2 or Doc-treated LNCaP and LN-AI cells but not in
DU145 cells (Fig. 1B).
To determine the effect of 2ME2 on NF-κB transcrip-
tional activity, we used a plasmid containing the
luciferase reporter regulated by NF-κB cis-acting ele-
ments. The results showed that 2ME2 increased NF-κB
activity ~2-fold in LNCaP cells at 24 and 72 h compared
to control treated cells (Fig. 1C). In contrast, 2ME2
slightly decreased NF-κB activity 1.5-fold in PC3 cells at
24 h but not at 72 h. The results also showed a 7.3-fold
higher basal NF-κB activity in PC3 compared to LNCaP
cells.
Nucleolar Localization of p65 in LNCaP cells Treated with 
Anitmitotic Drugs
We used fluorescence immunocytochemistry to deter-
mine if p65 localizes to the nucleus after 2ME2 treatment
of LNCaP cells. In control cells, p65 localized in the cyto-
plasm but after 24 h treatment with 5 μM 2ME2, some
cells appeared to have p65 localization to the nucleolus,
similar to a previous report [38]. Double fluorescence
immunocytochemistry confirmed the presence of several
cells with localization of p65 to the nucleolus, as revealed
by merged images of the nucleolar marker nucleolin
(Texas Red) with p65 (FITC), and DAPI nuclear stain
(blue) (Fig. 2). There was also co-localization of p65 and
nucleolin in the cytoplasm (yellow), likely due to the dis-
ruption of the nucleolus and nuclear membrane by anti-
mitotic drugs. The nucleolus is normally disassembled
during mitosis and reassembled after cell division [39].
These results suggest that in LNCaP cells treated with
antimitotic drugs, p65 can localize to the nucleolus,
which has previously been shown to be important in
increasing apoptosis in colon cancer cells treated with
aspirin [38].
NF-κB Inhibition Blocks Apoptosis Induced by Antimitotic 
Drugs
To determine whether 2ME2- or Doc-mediated activa-
tion of NF-κB in LNCaP cells is important for stimulating
apoptosis, we used the NF-κB inhibitor parthenolide [40].
Treatment of LNCaP cells with 10 μM parthenolide low-
ered apoptosis induced by 2ME2 or Doc, as determined
by the DAPI apoptosis assay and decreased levels cleaved
PARP protein (Fig. 3). Parthenolide lowered the 2ME2- or
Doc-mediated increase in phospho-IκBα and phospho-
p65, suggesting inhibition of NF-κB activity. These results
indicate that 2ME2- or Doc-mediated increase in NF-κB
activity is important for induction of apoptosis in LNCaP
cells. Similar results were obtained in LN-AI cells (result
not shown).
To further investigate molecular changes involved in
why inhibition of NF-κB reduced 2ME2- or Doc-medi-
ated apoptosis, we analyzed the expression of p53 and
XIAP. p53, the most commonly mutated gene in human
cancers, can mediate the apoptosis response to chemo-
therapy [41]. Overexpression of IAP family members
such as XIAP blocks apoptosis and increases drug resis-
tance [42]. Similar to our previous results, 2ME2 and Doc
increased p53 and decreased XIAP proteins in LNCaP
Figure 2 2ME2 increases p65 nucleolar localization in LNCaP cells. Double immunofluorescence showing localization of p65 to the nucleolus in 
LNCaP cells treated with 2ME2 for 24 h. In control LNCaP cells, p65 (green) is cytoplasmic, nucleolin (red) is in the nucleolus, DAPI (blue) stains the 
nucleus, and the merge of p65/nucleolin/DAPI shows no co-localization of p65 and nucleolin or DAPI. In 2ME2 treated LNCaP cells, p65 remains mostly 
cytoplasmic but some is localized within the nucleus; nucleolin is localized to the cytoplasm and some remains in the nucleolus or nucleus; DAPI 
shows mitotic cells. The merge of p65/nucleolin/DAPI shows some cells (arrows 1) with co-localized p65/nucleolin within the nucleolus (white) and 
within the cytoplasm (yellow). Also shown is a cell (arrow 2) with no co-localization of p65 and nucleolin. (×200).
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and LN-AI cells [28,35]. However, parthenolide blocked
the 2ME2 and Doc-induced changes in p53 and XIAP rel-
ative to control levels (Fig. 3). These results suggest that
the 2ME2- or Doc-mediated increase in NF-κB activity
correlates with increased p53 and decreased XIAP, condi-
tions that favor the induction of apoptosis.
Dominant Negative IκBα and p65 Knockdown Inhibit 2ME2 
and Doc Apoptosis
To further determine if there is a role for activation of
NF-κB in 2ME2- or Doc-mediated apoptosis, we isolated
Figure 4 Inhibition of NF-κB with dominant negative IκBα (dnI) or 
p65 shRNA decreases apoptosis induced by 2ME2 and Doc. A. 
DAPI analysis showing that LN-AI/dnI clones 7 and 20 undergo less 
apoptosis (% condensed fragmented nuclei) when treated with 2ME2 
(M; 5 μM) or Doc (D; 1 nM) for 48 h compared to LN-AI/neo negative 
control (N). n = 8, four independent experiments; *, P < 5 × 10-5. B. 
Western blot analysis showing less cleaved PARP in LN-AI/dnI clones 7 
and 20 compared to LN-AI/neo (N) cells treated with M or D for 48 h. 
No cleaved PARP was detected in control (Cont) treated cells. Endoge-
nous phospho (P)-IκBα increases in LN-AI/dnI-7 and neo (N) cells but 
not in LN-AI/dnI-20 cells when treated with M or D for 24 h. Total levels 
of endogenous IκBα decrease in all cells treated with M or D compared 
to Cont treated cells. Transfected (tx) dnI protein (migrates slightly fast-
er than endogenous IκBα) remains in LN-AI/dnI clones 7 and 20 but is 
not detected in LN-AI/neo cells. ns, non-specific band. Coomassie blue 
stain of total protein is loading control. C. DAPI and Western blot anal-
ysis showing less apoptosis and cleaved PARP in p65 knockdown LN-
CaP/shp65-2 (p65) compared to control LNCaP/GFP (C) cells treated 
with 2ME2 or Doc for 72 h. n = 6, three independent experiments; *, P 
< 5 × 10-3.
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Figure 3 NF-κB inhibitor parthenolide blocks 2ME2 and Doc-me-
diated apoptosis in LNCaP cells. DAPI apoptosis analysis (% con-
densed fragmented nuclei) showing that parthenolide (P; 10 μM) 
blocks 2ME2 (M; 5 μM) and Doc (D; 1 nM) apoptosis in LNCaP (72 h) 
cells. n = 7, four independent experiments; *, P < 6 × 10-4. Western blot 
analysis shows that P inhibits the M and D increase in cleaved PARP (72 
h), P-IκBα/IκBα (24 h), P-p65/p65 (24 h), p53 (72 h), and the M/D de-
crease in XIAP (72 h). Coomassie blue stain of total protein is loading 
control.
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stably transfected LN-AI clones expressing dominant
negative IκBα (dnI) [30]. LN-AI/dnI clones 7 and 20 and
negative control LN-AI/neo cells were treated with 2ME2
or Doc for 48 h and the effect on apoptosis determined by
DAPI and cleaved PARP protein levels. Results showed
decreased apoptosis in LN-AI/dnI-7 and 20 compared to
LN-AI/neo cells (Fig. 4). As expected, there was an
increase in endogenous phospho-IκBα in all cells treated
with 2ME2 or Doc for 24 h but phospho-dnI was not
detected (faster migrating band in total IκBα blot; Fig.
4B). Similar results were obtained in LNCaP cells stably
expressing dnI (result not shown) or shRNA targeting
p65 (Fig. 4C). These results further support an important
role for NF-κB activation-mediated increase in apoptosis
by treatment with 2ME2 or Doc in LN-AI and LNCaP
cells.
Betulinic Acid (BA), an NF-κB Activator, Stimulates Cell 
Death in All Prostate Cancer Cells Treated with Antimitotic 
Drugs
Our results showed that the NF-κB inhibitor partheno-
lide antagonized apoptosis mediated by antimitotic drugs
in LNCaP and LN-AI cells. In DU145 or PC3 cells, par-
thenolide had little effect on 2ME2- or Doc-mediated cell
death, as shown by the trypan blue exclusion assay (Fig.
5). Thus, we determined whether addition of an NF-κB
activator could increase apoptosis by antimitotic drugs in
all types of PC cells. BA is a natural pentacyclic triterpe-
noid proposed to activate NF-κB [12]. Combination of
2ME2 or Doc with 10 μM BA increased apoptosis in LN-
AI cells compared to the single drugs, as determined by
DAPI, cleaved PARP protein levels, and annexin V-FITC/
PI flow cytometry (Figs. 6, 7). BA further increased phos-
pho-IκBα and phospho-p65 and decreased total IκBα
compared to 2ME2 or Doc alone in LN-AI and DU145
cells, suggesting enhancement of NF-κB activity (Fig. 6).
Similar results were obtained in LNCaP cells (results not
shown). In addition, BA increased NF-κB DNA binding
in LNCaP and DU145 cells as determined by EMSA
(result not shown). In DU145 and PC3 cells, despite
increased fragmented and condensed nuclei (DAPI), BA
+2ME2 or Doc did not increase cleaved PARP (substrate
Figure 6 NF-κB activator BA stimulates 2ME2 and Doc-mediated 
apoptosis in LN-AI and DU145 cells. DAPI apoptosis assay (% con-
densed fragmented nuclei) showing that BA (B; 10 μM) increases 2ME2 
(M; 5 μM) and Doc (D; 1 nM) apoptosis (MB and DB) in LN-AI (24 h) and 
DU145 (72 h) compared to M, B, and control cells. n = 6-8, three to four 
independent experiments; *, P < 0.004. Western blot analysis shows 
greater cleaved PARP in MB and DB compared to M, D, or B alone in LN-
AI but not in DU145 cells. MB and DB increases P-IκBα/IκBα and P-p65/
p65 in LN-AI and DU145 cells at 24 h compared to M, D, B, and control 
cells, suggesting activation of NF-κB. MB and DB decreases IκBα, p53 
and XIAP compared to M and D alone; B alone also decrease IκBα, p53, 
and XIAP compared to control cells. Coomassie blue stain of total pro-
tein is loading control.
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for active caspase) (Fig. 6 and not shown), suggesting cas-
pase-independent cell death.
Further supporting a role for activation of NF-κB in the
2ME2/Doc + BA combination is the observation that the
LN-AI/dnI clones underwent less apoptosis compared to
the LN-AI/neo negative control cells (Fig. 8A). Knock-
down of p65 in LNCaP and DU145 also lowered cell
death and cleaved PARP (Fig. 8B). In addition, pretreat-
ment of DU145 cells with parthenolide (10 μM) for 24 h
followed by 2ME2/Doc + BA/parthenolide lowered cell
death compared to DU145 cells treated without parthe-
nolide (Fig. 8C). Furthermore, PC cells treated with BA
alone or in c ombina tion wit h 2ME2 or Doc decr eased
IκBα and XIAP protein levels (Fig. 6). These results sug-
gest that enhancement of NF-κB activity by BA plays a
role in increasing cell death in PC cells treated with anti-
mitotic drugs.
Because cleaved PARP levels are not increased in
DU145 or PC3 cells treated with the 2ME2/Doc + BA
combination, we assessed whether there were any differ-
ences in total cell death by the trypan blue exclusion
assay. Results indicated a greater extent of cell death in
the 2ME2/Doc + BA combination compared to 2ME2,
Doc, or BA treatment alone (Fig. 8D). This result further
suggests that BA increases caspase-independent cell
death in DU145 and PC3 cells.
Apoptosis-Inducing Factor (AIF) Increases Cell Death by 
2ME2/Doc + BA
To investigate potential downstream effectors of
increased cell death mediated by BA, we analyzed the
expression of apoptosis-inducing factor (AIF), the first
identified protein involved in caspase-independent cell
death [43]. Upon cytotoxic insult, AIF is cleaved, released
from the mitochondria to the cytoplasm and translocates
to the nucleus where it causes caspase-independent DNA
fragmentation and cell death [32,43]. Western blotting
indicated that DU145 and LNCaP cells treated with
2ME2/Doc + BA increased nuclear AIF compared to sin-
gle drug treatment and control (Fig. 9A). Increased
nuclear AIF was also detected by immunofluorescent cell
staining of DU145 cells treated with 2ME2/Doc + BA and
compared to control cells (Fig. 9C).
In addition, we investigated the expression of AIFshort
(AIFsh) protein, an alternative transcription start site
coding for AIF corresponding only to the C-terminal pro-
death portion that translocates to the nucleus to induce
cell death [32]. Western blot and RT-qPCR analysis
showed that LNCaP cells treated with 2ME2/Doc + BA or
BA alone increased AIFsh protein and mRNA (2-5-fold)
compared to 2ME2 and Doc alone (Fig. 9B, D). IκBα, A20,
and DR5 mRNAs, genes known to be regulated by NF-κB
[1] also increased in LNCaP cells treated with the 2ME2/
Doc + BA combination (Fig. 10). In DU145 and PC3 cells,
there was also an increase in AIFsh protein after treat-
ment with 2ME2/Doc + BA or BA alone (Fig. 9B).
Finally, we analyzed if shRNA knockdown of AIF has
any effect on cell death induced by the 2ME2/Doc + BA
combination in LNCaP and DU145 cells. In LNCaP cells,
AIF shRNA reduced both total AIF and AIFsh protein
and lowered cell death compared to control LNCaP/
shGFP cells (Fig. 9E). In DU145 cells, AIF knockdown
also lowered cell death and cleaved PARP by the 2ME2/
Doc + BA combination (result not shown). We suggest
that the NF-κB activator BA increases expression of
AIFsh and stimulates caspase-independent cell death in
apoptosis resistant PC cells such as DU145.
Discussion
Treatment of cancer cells with chemotherapeutic drugs
often results in substantial heterogeneity in the response
to NF-κB activity. In some cases, NF-κB activation by
chemotherapeutic drugs elicits a pro-survival cellular
response and combination with inhibitors of NF-κB
improves efficacy [1,3,4]. However, depending on the
type of drug or cancer cell, activation of NF-κB can elicit
a pro-death response [6]. Our results indicated that
improving the cell death response to 2ME2 and Doc in
PC cells depends on stimulating rather than inhibiting
NF-κB activity. In contrast to what was observed with
NF-κB inhibitors, combination of 2ME2 or Doc with BA,
Figure 7 2ME2/Doc + BA combination increases annexin+ apop-
tosis and PI+ cell death greater than either alone. Flow cytometric 
analysis of annexin-FITC (apoptotic) and PI (dead) stained LN-AI (A) and 
DU145 (B) cells after treatment with M, D, B, MB, DB, and control (C) for 
24 h (LN-AI) and 48 h (DU145). The annexin+ and PI+ cells were mea-
sured from three independent experiments done in duplicate (n = 6). 
*, P < 0.04.
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an activator of NF-κB, increased cell death in androgen-
responsive as well as castration-resistant PC cell lines.
Therefore, our data suggests that a chemotherapy combi-
nation strategy utilizing antimitotic drugs with BA is
likely to be a more universally effective chemotherapeutic
strategy for PC.
Our data suggest that the combination of antimitotic
drugs with NF-κB inhibitors will have antagonistic effects
in a common type of PC cell typical of LNCaP and LN-AI.
Support for this observation comes from a report demon-
strating that bortezomib, a proteasome inhibitor that
lowers NF-κB activity by blocking degradation of IκBα,
inhibits Doc-induced apoptosis in LNCaP cells [44].
More importantly, recent clinical trials indicate that
patients with CRPC have no added benefit from borte-
zomib above Doc in one study and some antitumor activ-
ity in another study [45,46]. It is not yet known, however,
if more specific inhibitors of NF-κB in combination with
Figure 8 Activation of NF-κB by BA is important for increasing apoptosis/cell death in combination with 2ME2 or Doc. A. DAPI analysis show-
ing that LN-AI/dnI clones 7 and 20 undergo less apoptosis (% condensed fragmented nuclei) when treated with MB or DB for 24 h compared to LN-
AI/neo negative control (N). n = 6, three independent experiments; *, P < 0.04. Western blot analysis showing less cleaved PARP in LN-AI/dnI clones 7 
and 20 compared to LN-AI/neo (N) cells treated with MB or DB for 24 h. B. Trypan blue exclusion and Western blot analysis showing that knockdown 
of p65 in LNCaP/shp65-2 and DU145/shp65-1 lowers cell death (n = 6, three independent experiments; *, P < 0.003) and cleaved PARP when treated 
with MB or DB and compared to control (C) treated LNCaP/shGFP and DU145/shGFP cells. C. Trypan blue exclusion assay showing that DU145 cells 
pretreated (PT) with NF-κB inhibitor parthenolide (Pa; 10 μM) for 24 h then treated (T) with MB or DB + Pa for 48 h underwent less cell death (% dead 
cells) compared to cells not pretreated with Pa and treated with MB or DB. Also shown are cells pretreated and treated with Pa alone. n = 6-7, four 
independent experiments. *, P < 0.002. D. Trypan blue exclusion assay showing increase in cell death in DU145 and PC3 cells treated for 72 h with 
2ME2 + BA (MB) or Doc + BA (DB) compared to BA (B; 10 μM), 2ME2 (M; 5 μM), Doc (D; 1 nM) alone and control cells. n = 5-6, three independent ex-
periments; *, P < 0.004.
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Figure 9 BA increases AIF nuclear localization and expression of AIFsh in PC cells. A. Western blot analysis showing increase in nuclear AIF (57 
kd) in LNCaP (48 h) and DU145 (72 h) cells treated with MB compared to M, B, and control (C) cells. B. Western blot analysis of total protein lysates 
showing increase in AIFsh (35 kd) in MB, DB, and B treated LNCaP (48 h), DU145, and PC3 (72 h) compared to M, D, or C. Coomassie blue stain of total 
protein is loading control. C. Immunofluorescence showing increase in nuclear localization of AIF in DU145 cells treated with DB compared to C cells 
(72 h). In control DU145 cells, AIF (green) is cytoplasmic and the merge with nuclear PI stain (red) shows little nuclear localization. In DB treated DU145 
cells, the merge of AIF and PI shows some nuclear localization (arrows; yellow). (×200). D. RT-qPCR analysis showing increase in AIFsh mRNA in LNCaP 
cells treated 48 h with MB, DB, or B alone compared to M or D alone. AIFsh mRNA levels were relative to C = 1. n = 5, three independent experiments; 
*, P < 0.05. E. Knockdown of AIF reduces cell death in LNCaP cells treated with MB and DB. Trypan blue exclusion assay showing that LNCaP/shAIF-2 
(AIF) cells undergo less cell death compared to control LNCaP/shGFP (C) after treatment for 24 h with MB or DB. n = 6, three independent experiments; 
*, P < 0.02. Western blot analysis showing knockdown of AIF and AIFsh proteins in LNCaP/shAIF-2 results in lower cleaved PARP after MB or DB treat-
ment compared to control LNCaP/shGFP cells. Coomassie blue stain of total protein is loading control.
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antimitotic drugs will have a better therapeutic effect
clinically, especially since constitutive NF-κB activity is
very prominent in CRPC [14-16].
Our results are similar to a previous report showing
that inhibition of NF-κB with dnI or the NF-κB inhibitor
BAY 117082 blocks 2ME2-induced apoptosis in LNCaP
cells [23]. Others have shown that 2ME2 can inhibit NF-
κB in PC3 and medulloblastoma/glioma cell lines and
blocking the Doc increase in NF-κB can enhance apopto-
sis in a variety of cancer cell lines [47-51]. Overall, the
heterogeneity implicated in the NF-κB response to anti-
cancer drugs is dependent on the specific type of drug
and cancer cell.
In LNCaP and LN-AI cells, the requirement of 2ME2
and Doc to activate NF-κB and increase apoptosis may
depend upon the p53 tumor suppressor protein [37].
There is evidence suggesting a link between activation of
NF-κB and the ability of p53 to induce apoptosis [7,52].
Our results in LNCaP cells indicated that 2ME2
increased nucleolar localization of p65 (Fig. 2). Nucleolar
localization of p65 has been previously reported in colon
cancer cells treated with aspirin and a model is proposed
that the nucleolus sequesters p65 and inhibits its anti-
apoptotic functions [38]. Interestingly, the ARF tumor
suppressor protein is localized to the nucleolus and after
activation by oncogenes can prevent Hdm2 from target-
ing p53 for degradation and therefore increases the stabil-
ity of p53 [53]. In addition, ARF can modulate p65
transcriptional activity to repress antiapoptotic genes in a
p53 independent manner [54]. One of the effects of anti-
mitotic drugs is the disruption of the nucleolus, the
release of ARF, and sequestration of Hdm2, which then
leads to the stabilization of p53 and subsequent induction
of apoptosis [55]. Our results suggest that investigating
the mechanistic basis of p65 nucleolar localization is
likely to yield significant insights regarding how to opti-
mize the cytotoxic antitumor action of antimitotic drugs.
It is known that the ability of BA to kill cancer cells
occurs by multiple signaling pathways including through
activation of NF-κB [12,56]. One potential mechanism for
NF-κB activation and increase in apoptosis by BA is the
degradation of IκBα and XIAP (Fig. 6). Activation of
selective proteasome-dependent degradation of Sp1, 3,
and 4 transcription factors controlling the proangiogenic
gene VEGF and the antiapoptosis gene survivin by BA
has been recently reported [57].
The pro-death effects of BA are independent of p53,
which is a desirable characteristic for any agent utilized
for the treatment of advanced PC, which frequently lacks
functional p53 [58]. Our data show that despite a
decrease in p53 protein, BA can still increase apoptosis or
cell death in all PC cells (Fig. 6). Our results also suggest
that BA combined with 2ME2 or Doc increases cell death
in a caspase-independent manner (Figs. 6, 7B, 8D). We
suggest that one of the factors that allow DU145 cells to
overcome the defect in the apoptosis pathway (mutant
p53/null Bax) is the increased nuclear translocation AIF/
AIFsh to mediate non-apoptotic cell death.
Conclusions
Combination chemotherapy is required to further
improve the survival of patients with CRPC. A prevailing
strategy has been to inhibit the NF-κB response in order
to block its pro-survival effect and improve drug efficacy.
In this study, we demonstrated that in PC cells such as
LNCaP and LN-AI, activation of NF-κB by the antimi-
totic agents 2ME2 or Doc is important for increasing
apoptosis. In addition, when 2ME2 or Doc is combined
with an NF-κB activator such as BA, there is effective
induction of cell death in all the PC cells analyzed. We are
currently investigating whether other NF-κB activators
will also mediate increased cell death by antimitotic
drugs. The combination of antimitotic agents with NF-κB
activators may promote the pro-death responses in a
greater variety of PC cells, a requirement for increased
therapeutic efficacy.
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Figure 10 BA increases and parthenolide decreases expression of 
NF-κB target genes. RT-qPCR analysis showing that BA (B; 10 μM) in-
creases expression of IκBα (top left), DR5 (top right), and A20 (bottom 
left) mRNAs in combination with 2ME2 (M; 5 μM) or Doc (D; 1 nM) (MB, 
DB) in LNCaP cells (48 h). Parthenolide (P; 10 μM) decreases the M and 
D increase in A20 (MP, DP) in LNCaP cells (72 h) (lower right panel). 
mRNA levels are normalized to control (C) = 1. n = 5, three indepen-
dent experiments. *, P < 0.05.
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